

*As  
and*  
64. A binding reagent specific for the marker diagnostic, prognostic or indicative of appropriate therapy for a disease state of claim 63.

65. The binding reagent of claim 64 bound to a detectable label. - -

**REMARKS**

The Examiner identified twenty-four groups of claims:

Applicants elect with traverse group 13, claim 39.

Claim 39 is directed to a method of identifying drugs.

Claims 40, 43 and 44 are dependent on claim 39 and thus incorporate all of the elements of claim 39.

Claim 41 and 42 also are dependent on claim 39 and thus incorporate all of the elements of claim 39.

New claims 56 and 57 depend on claim 39.

Claims 27 and 28 recite essentially the same method steps as that of claim 39 and thus a search of claims 39, 56 and 57 would accomplish a search of claims 27 and 28 as well.


New claims 58 – 65 depend directly or indirectly from claim 27 and thus incorporate the elements of claim 27.

Hence, it is requested respectfully that the restriction of certain claims be collapsed because a search of claim 39 would encompass claims other than claim 39. That would reduce the burden of applicants in view of the separation of claims into many groups.

Accordingly, in view of the above arguments, it is respectfully requested that claims 27, 28, 39 – 44 and 56 – 65 be examined in the application.

Favorable consideration, collapse of restriction of certain groups of claims and early indication of allowance of claim 27, 28, 39 – 44 and 56 – 65 are requested respectfully.

Respectfully submitted,



Dean H. Nakamura  
Reg. No. 33,981

Roylance, Abrams, Berdo & Goodman, L.L.P.  
1300 19<sup>th</sup> Street, N.W., Suite 600  
Washington, D.C. 20036  
(202) 659-9076  
Dated: 31 December 2002